SynthesisIET nanobiotechnology2025
Nanoparticles as an Alternative Strategy for the Rapid Detection of
Synthesis in IET nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multisystemic Tuberculosis Masquerading as Aggressive Cardiac Tumor Causing Budd-Chiari Syndrome Disseminated to the Brain Resulting in Death of a Six-Year-Old Boy.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, tuberculosis (TB) ranks as a second leading cause of death. The End TB strategy targets eliminating TB by 2030. Achieving this goal requires an early, accurate, and affordable diagnosis applicable in low- and middle-income countries; increasing the reach of point-of-care (POC) diagnostics is essential. Nanodiagnostics aims to enhance clinical diagnostic procedures with heightened sensitivity and accuracy by focusing on distinctive markers for early detection. A systematic search of research articles was conducted in four databases (PubMed, Scopus, Web of Science, and ScienceDirect) independently by two researchers. Publications retrieved in the independent search were mixed and imported into a single EndNote X8. The extraction of characteristics from the selected studies were carried out step by step by two independent researcher groups Abayeneh Girma and Fentaye Kassawmar and Yeshiwas Kassa and Yeshwas Asrat using a standardized data extraction format in Microsoft Excel 2021. Finally, the extracted data were combined and clearly presented in the table with the key information and findings. Inconsistencies between reviewers were resolved by discussion, and articles were included after consensus was reached. Totally, 2740 articles were retrieved, and 69 TB nanoparticle (NP)-based assays have fulfilled the inclusion criteria and included in this systematic review. The proposed platforms share the characteristics of accuracy, affordability, and swift time-to-result. Nanodiagnostics for TB now cover all clinical presentations of the disease, including active, drug-resistant, HIV-related, latent, and extrapulmonary TB. These advancements not only enhance the diagnostic landscape but also facilitate timely and effective treatment strategies, ultimately aiming to reduce the burden of TB worldwide. This review summarizes state-of-the-art knowledge of TB nanodiagnostics for the last 18 years. For fabrication concepts, detection strategies, and clinical performance, special consideration is given using various clinical specimens, and the suitability of TB nanodiagnostics for optimal MTB testing is evaluated. TB nanodiagnostics present a promising solution for meeting the stringent demands to end the TB epidemic by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.